ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0752

Intervening on Adverse Childhood Experiences in SLE—Self-Efficacy as a Potential Target

Kimberly DeQuattro1, Andrea Seet1, Laura Trupin2, Stephanie Rush1, Kamil Barbour3, Maria Dall'Era4, Jinoos Yazdany1 and Patricia Katz1, 1University of California San Francisco, San Francisco, CA, 2UC San Francisco, San Francisco, CA, 3Centers for Disease Control, Atlanta, GA, 4University of California San Francisco, Corte Madera, CA

Meeting: ACR Convergence 2021

Keywords: Patient reported outcomes, Systemic lupus erythematosus (SLE), Trauma

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Modifiable adaptations to adversity such as resilience (the ability to recover from difficulty) and self-efficacy (the belief in one’s ability to succeed in a situation) may be protective for those with SLE who experience stress. We previously reported that patients with a history of adverse childhood experiences (ACEs) demonstrate worse patient-reported outcomes. There are gaps in how to ameliorate poor outcomes among patients who experienced ACEs. We seek to identify patterns of adaptations to adversity as potential targets for future interventions in this population.

Methods: Data are from the California Lupus Epidemiology Study (CLUES), a diverse sample of adult SLE patients with confirmed diagnosis of SLE (met (a) ≥4/11 ACR 1982/1997 criteria for the classification of SLE, (b) 3/11 ACR 1982/1997 criteria and treating rheumatologist’s diagnosis of SLE, or (c) diagnosis of SLE nephritis). Participants completed a 10-item ACE questionnaire (range 0-10), a 4-item Brief Resilience Coping Score (BRCS, range 0-12), and the PROMIS self-efficacy survey. We examined associations for patient-reported measures of disease activity (SLAQ) and depression (PHQ-8) as well as ACEs with BRCS and self-efficacy using ANOVA and linear regression, controlling for age, gender, race/ethnicity, education, and disease duration. We also tested for interactions between ACE scores and resilience/self-efficacy.

Results: Of the 205 participants, 91.7% were female and 69.3% were non-white, with a mean ACE score of 1.76 (SD 2.1). Resilience was at the middle of the scale range (mean 8.4, SD 2.0) and the self-efficacy PROMIS measure was near the mean for the population distribution (mean 49.0, SD 9.1). There were similar levels of resilience and self-efficacy across ACE score categories (Table 1). As depicted (Table 2), there were significantly worse SLAQ and PHQ scores for people with higher ACE scores compared to people in the low ACE score category (0-1). Resilience showed no significant independent effect on SLAQ or PHQ, but self-efficacy was associated with better PHQ scores and SLAQ scores, although the latter did not reach statistical significance. Interactions between ACE score and resilience/self-efficacy were not statistically significant.

Conclusion: Individuals with SLE with the highest ACEs exposures reported high disease activity and depression. Resilience did not show protective effects on the outcomes examined in this cohort. However, self-efficacy, for which interventions have been developed, was associated with less depression, suggesting the potential for interventions targeting self-efficacy to improve outcomes. Experiencing ACEs did not affect whether a participant was more or less resilient or self-efficacious. Additional targets for interventions, such as social support, merit exploration to better bolster SLE patients with a history of ACEs.


Disclosures: K. DeQuattro, None; A. Seet, None; L. Trupin, None; S. Rush, None; K. Barbour, None; M. Dall'Era, AstraZeneca, 2, Aurinia, 2, Biogen, 2, Bristol Myers Squibb, 2, GlaxoSmithKline, 2, Pfizer, 2; J. Yazdany, Astra Zeneca, 2, 5, Pfizer, 2, 6, Gilead, 5, BMS Foundation, 5; P. Katz, None.

To cite this abstract in AMA style:

DeQuattro K, Seet A, Trupin L, Rush S, Barbour K, Dall'Era M, Yazdany J, Katz P. Intervening on Adverse Childhood Experiences in SLE—Self-Efficacy as a Potential Target [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/intervening-on-adverse-childhood-experiences-in-sle-self-efficacy-as-a-potential-target/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intervening-on-adverse-childhood-experiences-in-sle-self-efficacy-as-a-potential-target/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology